黒人成人の初期スクリーニング訪問での非到着の予測要因:GoFresh試験からのデータ

Benjamin Grobman¹, Christian Rivera¹, Mingyu Zhang¹

¹Harvard Medical School, Boston, MA, United States of America; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States of America.

Contemporary clinical trials

|August 21, 2025

まとめ

年配の参加者は最初の研究訪問に参加する可能性が高くなった. 家族の大きさと接触と訪問の間の遅延などの要因は,未到着と関連しており,試験採用の成功に影響を及ぼしました.

科学分野:

臨床試験
公衆衛生の介入
健康の格差

背景:

臨床試験の完了には重要な障壁として,研究訪問に参加者が来ないことが挙げられます.
臨床試験の成功に影響する要因を理解することは極めて重要です

研究の目的:

初期スクリーニング訪問に欠席した参加者と試験プロセスの特徴を特定する.
2つのランダム化制御試験 (GoFreshとGoFreshRx) の出席率に影響を与える要因を調査する.

主な方法:

2つの高血圧試験における2224人の参加者における社会人口学的および研究関連要因を調査した.
最初のスクリーニング訪問で到着しないとの関連を分析するためにロジスティック回帰を使用し,主要変数を調整しました.

主要な成果:

最初のスクリーニング訪問の非到着率は29.5%でした.
高齢者は出席率が高く家族の規模が大きくなり連絡と訪問の間の時間が長くなるのが欠席率と関連していた.
訪問の時間,季節,連絡方法は,出席率に大きな影響を与えない.

結論:

高齢,より大きな家族,最初の接触と訪問の間の長い遅れは,到着しないことに関連する重要な要因です.
これらの発見は,参加者の出席率を改善し,採用目標を達成するための介入の潜在的なターゲットを示唆しています.

キーワード:

格差高血圧採用について試練

さらに関連する動画

06:01

Collecting Hair Samples for Hair Cortisol Analysis in African Americans

Published on: June 10, 2018

18.4K

06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K

関連する概念動画

01:29

Bias in Epidemiological Studies

675

Biases can arise at various stages of research, from study design and data collection to analysis and interpretation. Recognizing and addressing these biases is essential to ensure the validity and reliability of epidemiological findings.Broadly speaking, biases in epidemiology fall into three main categories: selection bias, information bias, and confounding. A more detailed description of possible biases is:

675

02:16

Surveys

15.4K

Often, psychologists develop surveys as a means of gathering data. Surveys are lists of questions to be answered by research participants, and can be delivered as paper-and-pencil questionnaires, administered electronically, or conducted verbally. Generally, the survey itself can be completed in a short time, and the ease of administering a survey makes it easy to collect data from a large number of people.

15.4K

02:20

Longitudinal Research

12.5K

Sometimes we want to see how people change over time, as in studies of human development and lifespan. When we test the same group of individuals repeatedly over an extended period of time, we are conducting longitudinal research. Longitudinal research is a research design in which data-gathering is administered repeatedly over an extended period of time. For example, we may survey a group of individuals about their dietary habits at age 20, retest them a decade later at age 30, and then again...

12.5K

01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

114

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

114

01:20

Study Designs in Epidemiology

415

Epidemiological study designs are fundamental tools for investigating the distribution, determinants, and control of health conditions in populations. They help researchers understand the relationships between exposures and outcomes, and they broadly fall into two categories: "observational" and "experimental" studies.
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...

415

01:11

Clinical Trials: Overview

3.4K

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...